{"id":"conventional-paclitaxel-or-taxol","safety":{"commonSideEffects":[{"rate":"52–80","effect":"Neutropenia"},{"rate":"49–60","effect":"Peripheral neuropathy"},{"rate":"60","effect":"Myalgia/arthralgia"},{"rate":"80","effect":"Alopecia"},{"rate":"52","effect":"Nausea/vomiting"},{"rate":"43","effect":"Diarrhea"},{"rate":"2–12","effect":"Hypersensitivity reactions"},{"rate":"47","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Paclitaxel is a taxane that binds to the β-subunit of tubulin dimers and promotes microtubule assembly while inhibiting disassembly. This leads to stabilization of the microtubule cytoskeleton, disrupting normal mitotic spindle dynamics and causing cells to arrest in the G2/M phase of the cell cycle, ultimately triggering apoptosis. It is effective against a broad range of solid tumors.","oneSentence":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:36.564Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic carcinoma of the ovary"},{"name":"Breast cancer (metastatic and adjuvant)"},{"name":"Non-small cell lung cancer"},{"name":"Kaposi's sarcoma"},{"name":"Various solid tumors (phase 3 pipeline)"}]},"trialDetails":[{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":"Triple Negative Breast Cancer, Vitamin D Deficiency, Invasive Breast Cancer","enrollment":50},{"nctId":"NCT03517449","phase":"PHASE3","title":"Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2018-06-11","conditions":"Endometrial Neoplasms","enrollment":827},{"nctId":"NCT04883281","phase":"PHASE2","title":"A Prospective Study of Daily Adaptive Radiotherapy to Better Organ-at-Risk Doses in Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-02-23","conditions":"Head and Neck Cancer","enrollment":50},{"nctId":"NCT01970722","phase":"PHASE1","title":"Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-05-19","conditions":"FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Carcinoma","enrollment":40},{"nctId":"NCT01196390","phase":"PHASE3","title":"Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-14","conditions":"Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7","enrollment":203},{"nctId":"NCT05945732","phase":"","title":"DESTINY Breast Respond HER2-low Europe","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-10-24","conditions":"Unresectable Breast Cancer, Metastatic Breast Cancer, HER2-low Expressing Breast Cancer","enrollment":1155},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT06135714","phase":"PHASE3","title":"Metastasis-directed Therapy for Oligometastases of Breast Cancer","status":"RECRUITING","sponsor":"Tokyo Medical and Dental University","startDate":"2023-11-08","conditions":"Breast Cancer, Oligometastasis, Metastatic Breast Cancer","enrollment":340},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT05624996","phase":"PHASE3","title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-07-12","conditions":"Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":474},{"nctId":"NCT07328854","phase":"PHASE3","title":"40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Ming-Yuan Chen","startDate":"2025-11-20","conditions":"Nasopharyngeal Carcinoma","enrollment":346},{"nctId":"NCT07251062","phase":"PHASE2, PHASE3","title":"A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-12-30","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":737},{"nctId":"NCT01750073","phase":"PHASE2","title":"Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Nebraska","startDate":"2012-12-07","conditions":"Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":92},{"nctId":"NCT06543576","phase":"PHASE1, PHASE2","title":"External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2025-07-29","conditions":"Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma","enrollment":35},{"nctId":"NCT07052669","phase":"PHASE3","title":"Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-07-01","conditions":"Locally Advanced Non-Small Cell Lung Cancer","enrollment":311},{"nctId":"NCT05862064","phase":"PHASE3","title":"A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2023-06-01","conditions":"TNBC - Triple-Negative Breast Cancer","enrollment":606},{"nctId":"NCT06914440","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-06-05","conditions":"Breast Cancer","enrollment":27},{"nctId":"NCT06906887","phase":"PHASE2","title":"PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2025-06-17","conditions":"Esophageal Cancer, Oesophageal Cancer, GastroEsophageal Cancer","enrollment":50},{"nctId":"NCT02730546","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2016-06-24","conditions":"Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7","enrollment":31},{"nctId":"NCT02713386","phase":"PHASE1, PHASE2","title":"Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2016-11-14","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma","enrollment":147},{"nctId":"NCT06942416","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-28","conditions":"Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic","enrollment":36},{"nctId":"NCT04296175","phase":"PHASE3","title":"Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2020-03-05","conditions":"Triple-negative Breast Cancer","enrollment":808},{"nctId":"NCT06867562","phase":"PHASE3","title":"Paclitaxel Lipid Suspension for Patients with Platinum-Resistant /Refractory Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jina Pharmaceuticals Inc.","startDate":"2025-04","conditions":"Platinum-Resistant Primary Peritoneal Carcinoma, Platinum Resistant High Grade Epithelial Ovarian Cancer, Platinum Resistant High Grade Serous Ovarian Cancer","enrollment":166},{"nctId":"NCT06794801","phase":"NA","title":"Evaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2025-01","conditions":"ST Segment Elevation Myocardial Infarction (STEMI)","enrollment":134},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT05824975","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2023-05-30","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)","enrollment":358},{"nctId":"NCT06692491","phase":"PHASE2","title":"Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS","status":"NOT_YET_RECRUITING","sponsor":"Peking University Shenzhen Hospital","startDate":"2025-01-01","conditions":"Rare Tumour","enrollment":200},{"nctId":"NCT02689427","phase":"PHASE2","title":"Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-09-22","conditions":"Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7","enrollment":24},{"nctId":"NCT06542549","phase":"PHASE3","title":"Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody), Chemotherapy","enrollment":100},{"nctId":"NCT06532539","phase":"PHASE2","title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-06-13","conditions":"Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis","enrollment":30},{"nctId":"NCT01847326","phase":"PHASE1","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2013-03-26","conditions":"Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx","enrollment":48},{"nctId":"NCT06445881","phase":"PHASE2","title":"Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-01","conditions":"Non Small Cell Lung Cancer, Perioperative Complication","enrollment":60},{"nctId":"NCT00618657","phase":"PHASE2","title":"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2008-02","conditions":"Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer","enrollment":127},{"nctId":"NCT05273827","phase":"","title":"Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-03-22","conditions":"Immunotherapy, Analgesia, NSCLC","enrollment":81},{"nctId":"NCT02913274","phase":"NA","title":"Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty","status":"TERMINATED","sponsor":"Rennes University Hospital","startDate":"2017-03-20","conditions":"Stenosis of Arteriovenous Dialysis Fistula","enrollment":115},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT00499083","phase":"PHASE2","title":"Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-05-01","conditions":"Breast Cancer","enrollment":17},{"nctId":"NCT04989283","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-09","conditions":"Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT02427841","phase":"PHASE2","title":"Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2016-01-21","conditions":"Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma","enrollment":20},{"nctId":"NCT00033657","phase":"PHASE2","title":"Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2002-08-15","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":97},{"nctId":"NCT00014118","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Larynx or Oropharynx Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2001-06-06","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT05872880","phase":"","title":"TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma.","status":"RECRUITING","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-04-01","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":124},{"nctId":"NCT05872724","phase":"PHASE2","title":"Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)","status":"RECRUITING","sponsor":"Suzhou Municipal Hospital","startDate":"2023-01-16","conditions":"Cervical Cancer","enrollment":32},{"nctId":"NCT01147016","phase":"PHASE2","title":"Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2010-07","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT02315196","phase":"PHASE2","title":"Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2015-02-25","conditions":"Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer","enrollment":62},{"nctId":"NCT02930902","phase":"PHASE1","title":"Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-02-20","conditions":"Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7","enrollment":9},{"nctId":"NCT05524389","phase":"PHASE3","title":"Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2022-12-01","conditions":"Endometrial Cancer, Adjuvant Radiotherapy, Molecular Classification","enrollment":624},{"nctId":"NCT00373217","phase":"PHASE2","title":"Vaccine Therapy, Paclitaxel, and Carboplatin in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2006-04-13","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":6},{"nctId":"NCT05183958","phase":"PHASE2","title":"A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-12-31","conditions":"Esophageal Cancer","enrollment":118},{"nctId":"NCT03536182","phase":"PHASE3","title":"Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-05-29","conditions":"Locally Advanced Pancreatic Adenocarcinoma","enrollment":""},{"nctId":"NCT01183559","phase":"PHASE1","title":"A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery","status":"COMPLETED","sponsor":"Fox Chase Cancer Center","startDate":"2008-08-07","conditions":"Cancer of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Cancer of the Stomach","enrollment":9},{"nctId":"NCT00003930","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"1999-09","conditions":"Bladder Cancer","enrollment":84},{"nctId":"NCT01697293","phase":"PHASE1, PHASE2","title":"PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer","status":"TERMINATED","sponsor":"Prescient Therapeutics, Ltd.","startDate":"2012-01","conditions":"Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":34},{"nctId":"NCT00006469","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy Followed By Surgery in Treating Patients With Stage IIB or Stage IIIA Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Medstar Health Research Institute","startDate":"1999-08","conditions":"Lung Cancer","enrollment":30},{"nctId":"NCT00006472","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer","status":"TERMINATED","sponsor":"Medstar Health Research Institute","startDate":"2000-01","conditions":"Esophageal Cancer","enrollment":4},{"nctId":"NCT04502641","phase":"PHASE3","title":"Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-08-01","conditions":"Hypopharyngeal Cancer","enrollment":160},{"nctId":"NCT00915005","phase":"PHASE2","title":"Trial of Image-Guided Adaptive Conformal Photon vs Proton Therapy, With Concurrent Chemotherapy, for Locally Advanced Non-Small Cell Lung Carcinoma: Treatment Related Pneumonitis and Locoregional Recurrence","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":275},{"nctId":"NCT03785704","phase":"PHASE2","title":"Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer","status":"UNKNOWN","sponsor":"Peking Union Medical College","startDate":"2019-01-01","conditions":"Breast Neoplasms, Cardiac Event, Chemotherapeutic Toxicity","enrollment":60},{"nctId":"NCT04055038","phase":"PHASE2, PHASE3","title":"Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2019-09-01","conditions":"Ovarian Cancer, Ovarian Neoplasms, Serous Adenocarcinoma","enrollment":164},{"nctId":"NCT00513695","phase":"PHASE2","title":"Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2007-06","conditions":"Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer","enrollment":68},{"nctId":"NCT02194166","phase":"PHASE3","title":"A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-18","conditions":"Breast Cancer","enrollment":90},{"nctId":"NCT00011986","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-01","conditions":"Primary Peritoneal Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer","enrollment":4312},{"nctId":"NCT00807768","phase":"PHASE3","title":"Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer","status":"UNKNOWN","sponsor":"Gynecologic Oncology Group","startDate":"2009-03-23","conditions":"Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue","enrollment":601},{"nctId":"NCT01534585","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Taizhou Hospital","startDate":"2012-02","conditions":"Nasopharyngeal Carcinoma","enrollment":48},{"nctId":"NCT00194779","phase":"PHASE2","title":"Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-10","conditions":"Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer","enrollment":50},{"nctId":"NCT02392377","phase":"PHASE2","title":"Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-02","conditions":"Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma","enrollment":1},{"nctId":"NCT01544907","phase":"NA","title":"Prospective Randomized Trial Comparing DEB Versus Conventional PTA for the Treatment of Hemodialysis AVF or AVG Stenoses","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2012-01","conditions":"Stenosis of Arteriovenous Dialysis Fistula, Arteriovenous Graft Stenosis","enrollment":125},{"nctId":"NCT01688609","phase":"PHASE2","title":"Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-07","conditions":"HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer","enrollment":18},{"nctId":"NCT00006110","phase":"PHASE2","title":"Multimodality Treatment for Women With Stage II, Stage III, or Stage IV Breast Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"1998-12","conditions":"Breast Cancer","enrollment":82},{"nctId":"NCT00194792","phase":"PHASE2","title":"Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2005-08","conditions":"Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer","enrollment":28},{"nctId":"NCT03149913","phase":"NA","title":"Local Paclitaxel or Balloon Angioplasty Below the Knee","status":"UNKNOWN","sponsor":"Prof. Dr. med. Gunnar Tepe","startDate":"2016-12-15","conditions":"Stenosis, Occlusion, Restenosis","enrollment":120},{"nctId":"NCT00876486","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Samyang Biopharmaceuticals Corporation","startDate":"2008-12","conditions":"Breast Cancer","enrollment":213},{"nctId":"NCT00069953","phase":"PHASE2","title":"Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-09","conditions":"Esophageal Cancer","enrollment":43},{"nctId":"NCT00022139","phase":"PHASE2","title":"Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-01","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":56},{"nctId":"NCT00713557","phase":"","title":"Shanghai Registry of Acute Coronary Events","status":"TERMINATED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2005-03","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":20000},{"nctId":"NCT02891083","phase":"PHASE3","title":"Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2016-01","conditions":"Esophageal Neoplasms","enrollment":486},{"nctId":"NCT02772224","phase":"PHASE1","title":"Efficacy and Safety of Paclitaxel-eluting Balloons for Below the Knee Peripheral Arterial Disease","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-06","conditions":"Peripheral Arterial Disease","enrollment":180},{"nctId":"NCT01304784","phase":"PHASE1","title":"A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer","status":"COMPLETED","sponsor":"Merrimack Pharmaceuticals","startDate":"2011-01","conditions":"HER-2 Gene Amplification","enrollment":100},{"nctId":"NCT01238133","phase":"PHASE1","title":"Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-12","conditions":"Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative","enrollment":14},{"nctId":"NCT02513355","phase":"PHASE4","title":"Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-02","conditions":"Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT01083394","phase":"PHASE4","title":"Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2010-03","conditions":"Peripheral Vascular Disease","enrollment":70},{"nctId":"NCT00986752","phase":"PHASE4","title":"Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease","status":"UNKNOWN","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2009-07","conditions":"Peripheral Vascular Diseases","enrollment":150},{"nctId":"NCT02058433","phase":"PHASE3","title":"Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Caicun Zhou","startDate":"2014-01","conditions":"Non-Small Cell Lung Cancer","enrollment":140},{"nctId":"NCT00004094","phase":"PHASE2","title":"Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx","status":"UNKNOWN","sponsor":"National Cancer Institute (NCI)","startDate":"1999-08","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT00002894","phase":"PHASE3","title":"Platinum-based Chemotherapy With or Without Paclitaxel in Treating Patients With Relapsed Ovarian Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1996-03","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":800},{"nctId":"NCT00003159","phase":"PHASE3","title":"Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1997-08","conditions":"Lung Cancer","enrollment":600},{"nctId":"NCT00017303","phase":"PHASE2","title":"Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer","status":"UNKNOWN","sponsor":"Cytran","startDate":"2001-01","conditions":"Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":""},{"nctId":"NCT00533936","phase":"PHASE2","title":"Trastuzumab or Observation After Combination Chemotherapy and Trastuzumab in Treating Patients Undergoing Surgery for Stage II or Stage III Breast Cancer","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia, Columbia","startDate":"2006-09","conditions":"Breast Cancer","enrollment":160},{"nctId":"NCT00075712","phase":"PHASE2, PHASE3","title":"Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"Royal College of Obstetricians and Gynecologists","startDate":"2003-09","conditions":"Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer","enrollment":150},{"nctId":"NCT00070278","phase":"PHASE3","title":"Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer","status":"UNKNOWN","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2005-01","conditions":"Breast Cancer","enrollment":800},{"nctId":"NCT00002568","phase":"PHASE3","title":"Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"1994-06","conditions":"Ovarian Cancer","enrollment":470},{"nctId":"NCT00002852","phase":"PHASE3","title":"Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"1996-10","conditions":"Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer","enrollment":500},{"nctId":"NCT01887704","phase":"NA","title":"Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion","status":"COMPLETED","sponsor":"Capital Medical University","startDate":"2010-01","conditions":"Coronary Artery Disease","enrollment":240},{"nctId":"NCT00005065","phase":"PHASE1","title":"Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-01","conditions":"Stage IIIA Non-small Cell Lung Cancer","enrollment":12},{"nctId":"NCT01850147","phase":"PHASE2","title":"Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2013-03","conditions":"Cancer, Lung Cancer","enrollment":50},{"nctId":"NCT00014573","phase":"PHASE2","title":"Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"1998-08","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT00301028","phase":"PHASE2","title":"Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-04","conditions":"Head and Neck Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10155,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Conventional paclitaxel or Taxol","genericName":"Conventional paclitaxel or Taxol","companyName":"Jina Pharmaceuticals Inc.","companyId":"jina-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis in cancer cells. Used for Metastatic carcinoma of the ovary, Breast cancer (metastatic and adjuvant), Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}